Apellis Pharmaceuticals Announces That APL-2 Met Its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-...
August 24, 2017
MaxCyte, Inc. - First Day of Dealings on AIM
March 30, 2016
Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
November 8, 2017
Potentia Receives a Phase II STTR Grant
September 1, 2008
Louisville, Ky. – Potentia Pharmaceuticals, together with academic collaborators, received a Phase II STTR grant from the National Eye Institute to push forward their development of a new, less invasive delivery technology for ocular therapeutics. This grant, involving a collaboration with the Lions Eye Center of the University of Louisville, revolves around the use of disease-targeted drug-eluting polymeric nanoparticles that are administered intravenously.